MARKETING RESEARCH OF THE MARKET OF DRUGS WITH THE CHOLERETIC ACTION

Literary sources indicate that among hyperendemic diseases the problems of the biliary system take one of the leading places and are widely represented in all age groups. According to the Centre for Health Statistics of the Ministry of Public Health of Ukraine the number of patients with cholelithiasis grows, the increase in its prevalence for the last 10 years is 97.5%. The primary cause of the disease is the human life style, as well as conditions and the environment, genetic predisposition and activities of healthcare institutions. More often the treatment of cholelithiasis is associated with hospitalization and high financial cost. Annually there are more than 2.5 million operations on the bile ducts in the world. One of the alternative methods of treatment involves the use of drugs that are of natural and synthetic origin. Nowadays herbal medicines are gaining popularity. Prepared from herbs phytodrugs have a wide range of the therapeutic action with gradual, slow development of the therapeutic effect, high bioavailability, and patients can use them for a long time. Their action is not only aimed directly at treating disease, but also protecting and strengthening the organism as a whole. The aim of our work is to conduct the marketing research of the market of drugs with the choleretic action. It has been shown that the majority of the choleretic drugs range is formed by foreign producers, their share is 62% and domestic drugs are 38%. The countries importing drugs of the group under research have been studied. It has been proven that among the drugs with the choleretic action, tablets are the most common dosage form, their share is 55%. The results of the marketing analysis conducted allows to prove the expedience of creating combined medicinal products based on the plant raw material with a wide range of the therapeutic action that will have a high efficiency, quality and availability to the general public.

Literary sources indicate that among hyperendemic diseases the problems of the biliary system take one of the leading places and are widely represented in all age groups.According to the Centre for Health Statistics of the Ministry of Public Health of Ukraine the number of patients with cholelithiasis grows, the increase in its prevalence for the last 10 years is 97.5%.The primary cause of the disease is the human life style, as well as conditions and the environment, genetic predisposition and activities of healthcare institutions.More often the treatment of cholelithiasis is associated with hospitalization and high financial cost.Annually there are more than 2.5 million operations on the bile ducts in the world.One of the alternative methods of treatment involves the use of drugs that are of natural and synthetic origin.Nowadays herbal medicines are gaining popularity.Prepared from herbs phytodrugs have a wide range of the therapeutic action with gradual, slow development of the therapeutic effect, high bioavailability, and patients can use them for a long time.Their action is not only aimed directly at treating disease, but also protecting and strengthening the organism as a whole.The aim of our work is to conduct the marketing research of the market of drugs with the choleretic action.It has been shown that the majority of the choleretic drugs range is formed by foreign producers, their share is 62% and domestic drugs are 38%.The countries importing drugs of the group under research have been studied.It has been proven that among the drugs with the choleretic action, tablets are the most common dosage form, their share is 55%.The results of the marketing analysis conducted allows to prove the expedience of creating combined medicinal products based on the plant raw material with a wide range of the therapeutic action that will have a high efficiency, quality and availability to the general public.
At present, diseases of the biliary system take one of the leading places among hyperendemic diseases and are widely represented in all age groups.The prevalence of the disease is 45%, among young people it is 43% [2,3,16,18].
Foreign researchers have noted that in Europe and North America approximately 15% of the population suffer from cholecystitis [11,7,12].
In Ukraine, according to the Centre for Health Statistics of the Ministry of Public Health of Ukraine the number of patients with cholelithiasis grows, the increase in its prevalence for the last 10 years is 97.5%.
Prevalence of cholelithiasis is due to the factors that affect development of this disease (Fig. 1).
Fig. 1 shows that the main cause of the disease is the human life style, as well as conditions and the environment, genetic predisposition and activities of healthcare institutions.
More often the treatment of cholelithiasis is associated with hospitalization and high financial cost.
Annually there are more than 2.5 million operations on the bile ducts in the world.
The basis of the disease is metabolic disorders, cholestasia in the gallbladder and inflammation.Therefore, in order to prevent the symptoms of the disease an alternative method of treatment that involves administration of drugs is used [4,15].These drugs are both of natural and synthetic origin.According to the literature it is known that synthetic drugs may produce hepatotoxic effects and the possibility of developing dysbacteriosis [9,10].Synthetic drugs have also the limited range of the pharmacological action compared to phytodrugs.
Nowadays herbal medicines are gaining popularity.Phytodrugs prepared from herbs have a wide range of the therapeutic action with gradual, slow development of the therapeutic effect, high bioavailability, and patients can use them for a long time.Their action is not only aimed directly at treating disease, but also protecting and strengthening the organism as a whole [6,14].
The aim of our work is to conduct the marketing research of the market of drugs with the choleretic action.
Based on the literary sources it is known that there is a classification of choleretics [8, 19] (Tab.1).
Most drugs for cholelithiasis are represented by medicines of foreign production (Fig. 2).Their share is 62%.Domestic drugs are 38% of the range studied [5].
Foreign drugs are presented by 8 countries at the Ukrainian pharmaceutical market.Foreign manufacturers  are presented by such countries as Germany, the USA, Switzerland, Israel, Russia, France, Austria and China (Fig. 3).Fig. 4 presents the marketing analysis оf the choleretic drugs range according to the dosage forms.
Taking into account the results of the marketing research (Fig. 4), it has been found that the largest share is drugs with the choleretic action in the form of tablets (55%), half as large is in the form of capsules (21%), then there are solutions (7%), granules, teas, balms.The analysis shows the monocomponent composition of these medicines.
Popularity of manufacturing tablets is due to a number of their well-known advantages over other dosage forms: ease of use and storage, accuracy of dosing, the ability to combine medicinal substances incompatible by physical and chemical properties, and therapeutic effect, portability, etc. [1, 13,17].
The results of the marketing analysis conducted allows to prove the expedience of creating combined me-dicinal products based on the plant raw material with a wide range of the therapeutic action that will have a high efficiency, quality and availability to the general public.
CONCLUSIONS 1.The marketing research of the pharmaceutical market of drugs with the choleretic action has been carried out.
2. It has been shown that the majority of the choleretic drugs range is formed by foreign producers, their share is 62% and domestic drugs are 38%.
3. The countries importing drugs of the group under research have been studied.
4. It has been proven that among the drugs with the choleretic action, tablets are the most common dosage form, their share is 55%.
5. The expedience of creating domestic drugs with the choleretic action has been substantiated in order to increase the level of providing the population with effective, safe and available drugs.